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ABSTRACT 
 
Acute myeloid leukemia (AML) is a disease characterized by uncontrolled proliferation 
of immature myeloid cells in the blood and bone marrow. The five-year survival rate is 
approximately 25%, and recent therapeutic developments have yielded little survival 
benefit. Therefore, there is an urgent need to identify novel therapeutic targets. We 
previously demonstrated that acid ceramidase (ASAH1, referred to as AC) is 
upregulated in AML and high AC activity correlates with poor patient survival. Here, we 
characterized a novel AC inhibitor, SACLAC, that significantly reduced the viability of 
AML cells with an EC50 of approximately 3 µM across 30 human AML cell lines. 
Treatment of AML cell lines with SACLAC effectively blocked AC activity and induced a 
decrease in sphingosine 1-phosphate and a 2.5-fold increase in total ceramide levels. 
Mechanistically, we showed that SACLAC treatment led to reduced levels of splicing 
factor SF3B1 and alternative Mcl-1 mRNA splicing in multiple human AML cell lines. 
This increased pro-apoptotic Mcl-1S levels and contributed to SACLAC-induced 
apoptosis in AML cells. The apoptotic effects of SACLAC were attenuated by SF3B1 or 
Mcl-1 overexpression and by selective knockdown of Mcl-1S. Furthermore, AC 
knockdown and exogenous C16-ceramide supplementation induced similar changes in 
SF3B1 level and Mcl-1S/L ratio. Finally, we demonstrated that SACLAC treatment leads 
to a 37 to 75% reduction in leukemic burden in two human AML xenograft mouse 
models. 
 
IMPLICATIONS  
 
These data further emphasize AC as a therapeutic target in AML and define SACLAC 
as a potent inhibitor to be further optimized for future clinical development.  
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INTRODUCTION 
 
Acute myeloid leukemia (AML) is a malignancy of the blood and bone marrow, 
characterized by uncontrolled proliferation of immature myeloid blasts. The current 
prognosis for most patients is poor, with 5-year survival at only 27% (1). AML is more 
common in older populations, with a median age of 68 at diagnosis. Unfortunately, older 
patients have even worse prognoses, with only 7% of patients over the age of 65 
surviving 5 years past diagnosis (1–3). Patients generally receive a combination of 
general chemotherapeutics cytarabine (7 days) and daunorubicin (3 days) by 
continuous infusion. While new therapies have been approved recently, there is little 
change in overall survival. Some targeted therapies are available for patients with 
genetic mutations such as FLT3 and JAK2 (4), but AML is an extremely heterogeneous 
disease where the most recurrent genetic abnormality only exists in about 30% of 
patients (5–7). Treatment with FLT3 inhibitor quizartinib achieved about 50% composite 
complete remission for FLT3-ITD-positive patients, but only about 5% of patients 
achieved complete remission (8). 
 
There is an urgent need for novel therapeutics in AML due to the limitations of current 
treatment options and poor patient survival (9,10), especially in the aging population 
that cannot tolerate intensive therapy (2,11). There are several hurdles involved in AML 
treatment, including therapy-related toxicity (12), genetic heterogeneity, de novo drug 
resistance and relapse (13). Identification of therapeutics that address these issues 
could greatly influence the future of AML treatment and improve patient prognosis. 
 
An emerging area of study in cancer therapy involves manipulating sphingolipid 
metabolism in cancer cells to control cell fate (14). While sphingolipids are generally 
perceived as structural components of cellular membranes, there are two key bioactive 
sphingolipids at the center of this pathway. Ceramide is a known second messenger in 
cell death while sphingosine 1-phosphate (S1P) is pro-survival (15). Enzymes that 
mediate the conversion of ceramide to S1P are tightly regulated to maintain the balance 
between the integrity of healthy cells and the destruction of damaged cells. However, 
dysregulation of the enzymes regulating this pathway can contribute to many diseases 
including cancer (14,16,17). Acid ceramidase (ASAH1, referred to as AC) plays an 
important role in balancing these two lipids (17). AC is part of a family of lipid hydrolases 
that cleave ceramide to form sphingosine, which can be subsequently phosphorylated 
to produce S1P. AC is upregulated in several cancers (18–21). We recently established 
that it is the highest expressed and most upregulated ceramidase in AML and mediates 
survival of AML cells (22). We further demonstrated that elevated AC activity contributes 
to increased P-glycoprotein (P-gp) expression and a drug resistance phenotype in AML 
(23). Importantly, AC upregulation was observed in most AML patient samples, 
indicating that AC is a promising therapeutic target that may be applicable to a large 
percentage of AML patients. 
 
We previously demonstrated that AC inhibition with LCL204 coincided with a loss of pro-
survival Mcl-1 protein, leading to apoptosis (22). This finding is particularly relevant 
given the known importance of Bcl-2 family members in AML pathogenesis and 
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response to therapy (24). For example, upregulation of Mcl-1 is an established 
mechanism of resistance to the promising Bcl-2 inhibitor venetoclax, which is currently 
approved for use in elderly AML in combination with hypomethylating agents or low 
dose cytarabine (25–27). The full-length pro-survival Mcl-1 protein can also be referred 
to as Mcl-1L. However, Mcl-1 function can be altered through alternative mRNA splicing 
(28,29). When splicing is disrupted, exclusion of exon 2 results in formation of Mcl-1S. 
This step is regulated by SF3B1, a critical component of spliceosome assembly (28). 
Importantly, this alternative splicing event results in a dramatic change of function—Mcl-
1L is pro-survival while Mcl-1S is pro-apoptotic (30). Mcl-1S retains the functional BH3 
domain, which is critical for mitochondria-mediated induction of apoptosis (30,31). 
Previous studies have demonstrated that modulation of mRNA splicing can induce 
apoptosis of cancer cells (28,32). 
 
Here, we utilize AC inhibition to increase ceramide levels and induce selective toxicity of 
AML cells. Further, we characterize a novel AC inhibitor to determine its efficacy and 
mechanism of action in AML cell lines, patient samples and xenograft models. By 
targeting AC, we aim to exploit a common biochemical dependence in AML cells that 
may represent a therapeutic approach that is broadly applicable to the diverse 
population of AML patients.  
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MATERIALS AND METHODS 
 
Cell lines 
Kasumi-1, Kasumi-3, Kasumi-6, ME-1, SET2 and SKM-1 cells were cultured in RPMI-
1640 (Corning #10-040) with 20% FBS (VWR #97068-085). OCI-AML3 cells were 
cultured in RPMI-1640 with 15% FBS. OCI-AML4 cells were cultured in -MEM 
(ThermoFisher #12571063) with 20% FBS and supplemented with 100 ng/ml hGM-CSF 
(Milltenyi Biotec #130-095-372). All KG1 derivative cells and OCI-M2 cells were cultured 
in IMDM (ThermoFisher #12440) with 20% FBS. All other cell lines were cultured in 
RPMI-1640 media supplemented with 10% FBS. 
 
HL-60/VCR (33) cells were maintained in the presence of 1 µg/ml vincristine sulfate 
(Cayman #11764). HL-60/ABTR (34) cells were maintained in the presence of 5 µM 
ABT-737 (Cayman #11501). KG1/ABTR and KG1a/ABTR (34) cells were maintained in 
the presence of 1 µM ABT-737. Kasumi-6 and SNKO1 cells were supplemented with 10 
ng/ml hGM-CSF. TF-1 cells were supplemented with 2 ng/ml hGM-CSF. 
 
OCI-M2, SKNO1 and SKM-1 cell lines were obtained from DSMZ. All other cell lines 
were obtained from ATCC or kindly gifted according to the acknowledgements. All cells 
were grown at 37C and 5% CO2 in a humidified incubator. Cell lines were 
authenticated by short tandem repeat DNA profiling (Genetica DNA laboratories) and 
tested for mycoplasma contamination routinely using the MycoAlert PLUS detection kit 
(Lonza #LT07-710). Experiments were performed within 6 weeks of thawing. 
 
HL-60/VCR, OCI-AML2 and THP-1 cell lines were chosen for characterization studies 
based on prevalence in literature and ease of maintenance. KG1a cells were chosen for 
siRNA studies based on transfection efficiency with published electroporation 
parameters. A table of RRID numbers for these cell lines can be found in the 
Supplementary Appendix. 
 
AML patient samples 
Samples were prepared from peripheral blood collected from newly diagnosed and 
untreated AML patients. Mononuclear cells were isolated by Ficoll-Paque (GE 
Healthcare Life Sciences) density gradient centrifugation. Cells were cultured in the 
serum-free medium StemSpan SFEM (referred to as SFEM) purchased from Stem Cell 
Technologies and supplemented with recombinant human stem cell factor (SCF, 100 
ng/ml), interleukin-3 (IL-3, 20 ng/ml), FMS-like tyrosine kinase ligand (FLT3L, 100 
ng/ml), granulocyte colony-stimulating factor (G-CSF, 20 ng/ml) and granulocyte-
macrophage colony-stimulating factor (GM-CSF, 20 ng/ml) (Shenandoah 
Biotechnology). All cultures were incubated at 37°C with 5% CO2. Informed consent 
was obtained from all patients under Penn State College of Medicine Institutional 
Review Board-approved protocol according to the Declaration of Helsinki. 
 
Healthy donor samples 
PBMCs from healthy donors were obtained from Virginia Blood Services and enriched 
using the Ficoll-Paque gradient separation method. CD34+ PBMCs mobilized with G-
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CSF were obtained from the University of Virginia Health System Blood Bank. CD34+ 
cells were isolated from PBMCs with a Human CD34 MicroBead Kit (Miltenyi Biotec 
#130-046) using the autoMACS Pro Separator (Milltenyi Biotec #130-092-545).  
 
Compounds 
SACLAC N-[(2S,3R)-1,3-dihydroxyoctadecan-2-yl]2-chloroacetamide was synthesized 
as previously described (IQAC-CSIC) (35). The structure was validated using mass 
spectrometry. 2-Hydroxypropyl β-cyclodextrin was obtained from Acros Organics 
(#297561000). ABT-737 and ceramides mixture were obtained from Cayman Chemicals 
(#11501 and #22853, respectively). The ceramide mixture contained trace amount of 
C16 ceramide and varying amounts of longer chain and 2-hydroxy ceramides with C24 
species being most abundant. C16 was purchased from Avanti Polar Lipids (#860516). 
All ceramides were dissolved in methanol with 2% dodecane. LCL204 was synthesized 
according to previously published methods (36). RBM14C12 substrate for AC activity 
assays was provided by Gemma Fabrias and Antonio Delgado (IQAC-CSIC). 
 
Acid ceramidase activity assay 
Cells were seeded at 2 x 104 cells per well in 50 µl. Acid ceramidase activity was 
measured at 24 hours using the RBM14C12 fluorogenic substrate as previously 
described (22,37). 
 
Sphingolipid analysis 
Lipid extraction and analysis was done using liquid chromatography-electrospray 
ionization-tandem mass spectrometry (LC-ESI-MS/MS) as previously described (22). 
Cells were plated at 5 million cells per 6 ml and treated with SACLAC or DMSO for 24 
hours. Lipids were extracted from cell pellets using an azeotrophic mix of 
isopropanol:water:ethyl acetate (3:1:6; v:v:v). Internal standards (50 pmol of d17 long-
chain bases and C12 acylated sphingolipids) were added to samples at the onset of the 
extraction procedure. Extracts were separated on a Waters I-class Acquity UPLC 
chromatography system. Mobile phases were (A) 60:40 water:acetonitrile and (B) 90:10 
isopropanol:methanol with both mobile phases containing 5 mM ammonium formate 
and 0.1% formic acid. A Waters C18 CSH 2.1 mm ID × 10 cm column maintained at 
65°C was used for the separation of the sphingoid bases, 1-phosphates, and acylated 
sphingolipids. The eluate was analyzed with an inline Waters TQ-S mass spectrometer 
using multiple reaction monitoring. All data reported are based on monoisotopic mass 
and are represented as pmol/mg protein.  
 
Cell viability assay 
For cell viability, cell lines were plated at 2.5 x 104 cells per well in a 96-well plate and 
treated with SACLAC or DMSO vehicle (0.4% of total volume) for the indicated time 
points and doses. At the experiment end point, 3-(4,5-Dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) Cell Proliferation 
Colorimetric Assay Kit (BioVision # K300-5000) reagent was added and incubated for 2 
hours. Conversion of MTS to formazan product was measured by absorbance at 490 
nm using a BioTek Cytation 3 plate reader. Absorbance was normalized to DMSO 
control, which was defined as 100% viability. Due to limited cell numbers, patient 
on December 3, 2019. © 2019 American Association for Cancer Research. mcr.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on November 19, 2019; DOI: 10.1158/1541-7786.MCR-19-0619 
 8 
samples and normal samples were plated at 5x103 cells per well in a 384-well plate with 
SACLAC or DMSO control for the indicated time points and doses. At the experiment 
end point, CellTiter-Glo Luminescent reagent (Promega #G7572) was added. After 15 
minutes, luminescence was read on a BioTek Cytation 3 plate reader. Absorbance was 
normalized to DMSO control, which was defined as 100% viability.  
 
Colony forming assay 
Cryopreserved human AML patient samples were thawed and washed twice with RPMI 
1640 supplemented with 2% heat inactivated fetal bovine serum (FBS). After washes, 
cells were cultured in triplicate in 12-well plates at a density of 0.1 to 2 x 105 cells per 
well in Human Methylcellulose Complete Media (R&D Systems, #HSC003). Plating 
densities were selected for each case to yield colony outgrowth of 20-100 colonies per 
well. The desired cell number and dose of SACLAC or DMSO was added to the culture 
media and dispensed to multi-well plates. Colonies were propagated for 10-14 days and 
blast colonies (>20 cells) were counted in a blinded manner under the light microscope. 
 
Flow cytometry  
Apoptosis in cell lines was assessed after treating 2.5 x 105 cells per ml with drug or 
vehicle in a 48-well plate for the indicated time points and doses. Primary human AML 
cells were pre-incubated with SFEM for 48 hours before plating 2 x 105 cells in 24-well 
plates for the indicated times point and doses. Samples were stained using the Muse 
Annexin V & Dead Cell Kit (Millipore #MCH100105). Change in mitochondrial 
membrane potential in cell lines was measured with the Muse MitoPotential Kit 
(Millipore #MCH100110). Caspase activation was measured using the Muse Caspase 
3/7 Assay Kit (Millipore # MCH100108). For rescue experiments, cells were plated at 
2.5 x 104 well in a 96-well plate 24 hours after electroporation. Cells were treated with 
DMSO or SACLAC for 48 hours and apoptosis was detected as stated above. All kits 
were used according to manufacturer’s protocol. Cells were then analyzed using the 
Muse Cell Analyzer (38,39). Experiments included positive and negative controls for 
proper analysis. 
 
Western blotting 
Cells were plated at 2.5 x 105 cells per ml in 6-well plates and treated with drug, vehicle 
or siRNA at the indicated doses and time points. Cells were harvested, washed with 
PBS. Cells were lysed with RIPA buffer (Sigma #R0278) containing phosphatase 
inhibitor cocktails 2 and 3 (Sigma #P5726, #P0044) and protease inhibitor cocktail 
(Sigma #P8340). Protein was quantified using a bicinchoninic acid (BCA) protein assay 
kit (Pierce #23225). Samples were resolved on a Bolt 4-12% SDS-PAGE gel 
(ThermoFisher #NW00082) and transferred to PVDF membrane (Bio-Rad #170-4274). 
Antibodies were obtained from Cell Signaling Technology unless indicated otherwise. 
Primary antibodies used were: Mcl-1 (#5453, RRID #AB_10694494), SF3B1 (#14434, 
RRID #AB_2798479), -actin (#3700, RRID #AB_2242334), Bim (#2819, RRID 
#AB_10692515) and AC (BD Biosciences #612302, RRID #AB_399617). Secondary 
antibodies used were HRP-linked goat anti-mouse (#7076, RRID #AB_330924) or goat 
anti-rabbit IgG (#7074, RRID #AB_2099233). Clarity Max Western ECL Substrate (Bio-
Rad #1705062) was added to visualize relative protein expression by 
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chemiluminescence using the Bio-Rad ChemiDoc MP imaging system. Quantification 
was done using Bio-Rad ImageLab 6.0.1 software. For quantification, bands were 
normalized to -actin as a loading control. 
 
AC knockdown via siRNA electroporation or shRNA transduction 
KG1a cells were electroporated with non-targeting scrambled siRNA (Dharmacon #D-
001810-10-20), siRNA targeting ASAH1 (Dharmacon #L-005228-03-0010) or MCL-1S 
(Dharmacon #CTM-481502) using the Neon Transfection System (Invitrogen) according 
to the manufacturer’s protocol with the following parameters: 3 x 107 cells per ml, 1700 
pulse voltage, and 20 ms pulse width for a single pulse. AC knockdown cells were 
harvested 48 hours after transfection for analysis by western blot. Mcl-1S knockdown 
cells were re-plated to 2.5 x 105 cells per ml and treated with SACLAC 24 hours after 
electroporation. Control- and SACLAC-treated cells were harvested 48 hours after 
SACLAC treatment, corresponding to 72 hours after electroporation. HL-60/VCR cells 
were transduced with vectors expressing shRNA to target AC or GFP control as 
previously described (23). 
 
Overexpression with cDNA via electroporation 
KG1a cells were electroporated with empty vector, an M98 vector containing Mcl-1 
cDNA (NM_021960.4; Genecopoeia) or a pCMV vector containing a synthetic sequence 
for WT SF3B1 (40) using the same protocol listed above. The SF3B1 construct was 
sequence verified and the sequence of the codon-optimized coding region is available 
from the original authors.  
 
Quantitative reverse transcription PCR 
Cells were seeded at 2.5 x 105 cells per ml in 6-well plates and treated with DMSO or 
SACLAC for six hours. Cells were harvested and resuspended in TRIzol reagent 
(Invitrogen #15596026). RNA was isolated using Direct-zol RNA Miniprep Plus (Zymo 
Research #R2072) according to the manufacturer’s protocol. RNA was quantified using 
the Take3 microplate and the pre-programmed RNA quantification protocol on the Gen5 
software for the Cytation 3 plate reader (BioTek). DNase treatment and reverse 
transcription were done using the iScript gDNA Clear cDNA Synthesis Kit (Bio-Rad 
#1725035) in accordance with the manufacturer’s protocol. The qPCR reaction 
contained iTaq Universal SYBR Green (Bio-Rad #1725122), 140 ng cDNA and primers 
specific for HPRT (Bio-Rad #100-25636), B2M (Bio-Rad #100-25636) and MCL-1S 
(Eurofins; forward, 5’-GAGGAGGACGAGTTGTACCG-3’ and reverse, 5’-
ACTCCACAAACCCATCCTTG-3’) (41). This primer pair specifically amplifies Mcl-1 
transcript variant 2 (MCL-1S) according to BLAST analysis. CT values were normalized 
using B2M and HPRT housekeeping genes and transformed to 2-ΔCT and the DMSO 
control was set to 1. 
 
In vivo AML xenograft model 
Maximum tolerated dose of SACLAC was determined in NOD-scid IL2Rgammanull 
(NSG) mice (n=5; Jackson Laboratories). Mice were injected with SACLAC 
reconstituted in β-HPCD (IV) daily for 5 days at a dose of 5 mg/kg body weight, 
respectively. For pharmacokinetics studies, Swiss Webster mice (n=3; Charles River 
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Laboratories) were injected with SACLAC dissolved in DMSO (40 mg/kg body weight, 
intraperitoneally) or dissolved in β-HPCD (5 mg/kg body weight, via tail-vein injection). 
Mice were euthanized and blood was harvested at time points ranging from 0 to 48 
hours. Serum concentration of SACLAC was measured by mass spectrometry 
quantification relative to SACLAC standard using the method referenced above. 
 
To assess the efficacy of SACLAC in a transplantable human AML model, two cell line 
models were used. For the MV4-11 model, 2.5 x 106 luciferase (luc2)- and yellow 
fluorescent protein (YFP)-expressing MV4-11 cells (34) in HBSS were introduced into 6- 
to 8-week-old female NSG mice via tail-vein injections. After 10-12 days, engraftment 
was confirmed using bioluminescence imaging with the IVIS Lumina LT Series III 
imaging system (Perkin Elmer). Mice were equally randomized into two groups of three 
mice and treated with vehicle or SACLAC at 5 mg/kg/day five times per week for 18 
total injections. At the end of the treatment, animals were euthanized and peripheral 
blood was collected for flow cytometry analysis.  
 
For the U937 model, 1 x 104 luciferase and tdTomato-expressing U937 cells (Addgene 
#72486, kindly gifted by Kazuhiro Oka) in HBSS were introduced into 6- to 8-week-old 
female NSG mice via tail-vein injections. After six days, engraftment was confirmed as 
stated above. Mice were equally randomized into two groups of five mice and treated 
with vehicle or SACLAC at 5 mg/kg/day five times per week for 15 total injections. 
Animals were euthanized and bone marrow was collected for flow cytometry analysis. 
 
Red blood cells (RBC) were lysed with RBC Lysis Buffer (BioLegend #420301) followed 
by cell surface staining with anti-human CD45 antibodies (BioLegend #304014, clone 
HI30) and 7-AAD (BioLegend #420404) to detect viable human white blood cells (WBC) 
using an LSR II flow cytometer and BD FACS Diva software at the Penn State College 
of Medicine Flow Cytometry Core. Viable cells were identified by gating on 7AAD-
negative cells gated from singlets (SSC-A and FSC-W scales), after excluding the 
debris (SSC-A and FSC-A scales). Percentage of YFP, tdTomato or hCD45 positive 
cells was determined in FlowJo software (Becton Dickinson). 
 
All animal studies were performed with IACUC approval (PRAMS201246746). 
 
Statistical analysis  
Significance between two treatment groups was determined by the two-tailed unpaired 
t-test using the GraphPad Prism 7.0 software. Data sets containing multiple comparison 
were corrected using the Holm-Sidak method. Experiments containing dose response or 
time courses were analyzed using one-way ANOVA with Dunnett’s post-test to compare 
each condition to a single control. Cell line studies were repeated for three independent 
experiments, each with three or more technical replicates unless otherwise stated. One 
representative experiment is shown with error bars representing standard error of the 
mean (SEM).  
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RESULTS 
 
Previously published literature validated AC as a therapeutic target in AML while 
utilizing the small molecule inhibitor LCL204, which is clinically limited by lysosomal 
toxicity (22). To further investigate the potential of AC inhibitors for AML treatment, we 
tested a novel inhibitor that binds irreversibly to AC.  
 
SACLAC inhibits AC and shifts lipid levels toward a pro-death phenotype 
SACLAC is an α-chloroamide ceramide analog (Figure 1A) that binds irreversibly to AC 
by transferring a covalent adduct to the enzyme catalytic site (35). We expected that 
inhibition of AC with SACLAC would cause accumulation of ceramides by blocking the 
breakdown of ceramide to sphingosine and further conversion to S1P. Three human 
AML cell lines were selected to evaluate SACLAC inhibition of AC activity in AML. The 
multidrug resistant HL-60/VCR cell line, which overexpresses P-gp (23) was treated 
alongside THP-1 and OCI-AML2 cell lines with SACLAC (2.5 µM). AC activity of these 
cell lines was reduced by 98%, 71% and 100%, respectively, with 24-hour treatment 
(Figure 1B). This is superior to LCL204, which requires a four-fold higher dose to 
achieve similar effects (Figures S1). We measured changes in S1P and ceramides 
under the same conditions. SACLAC reduced S1P content by 87% in HL-60/VCR and 
reduced S1P levels to below the limit of detection in THP-1 and OCI-AML2 cell lines 
(Figure 1C). Further, these conditions led to a 2- to 3-fold increase in total ceramide 
production (Figure 1D). Most individual ceramide species increased upon SACLAC 
treatment, with the most pronounced changes being C16, C18, C22:1 and C24:2 
(Figure S2). Together these data indicate that SACLAC robustly inhibits AC activity and 
shifts lipid levels in the expected manner, increasing pro-death ceramides and 
decreasing pro-survival S1P. 
 
SACLAC reduces viability and colony formation 
Next, we determined if these shifts in lipid content were functionally significant and 
universally observed in human AML cell lines and patient samples. The same three 
representative cell lines were treated with SACLAC and cell viability was determined by 
MTS assay. HL-60/VCR, THP-1 and OCI-AML2, had half maximal inhibitory 
concentration (EC50) values in the low-micromolar range (3.3, 2.6 and 1.8 µM, 
respectively) with 24-hour treatment (Figure 2A). To determine if this effect translated 
to AML patient cells, colony formation was analyzed in a panel of six primary patient 
samples. These six primary patient samples showed a reduced ability to form colonies 
in the presence of increasing doses of SACLAC. On average, colony formation 
decreased 32% with 5 µM treatment and 69% with 20 µM treatment (Figure 2B). Since 
AML is a heterogeneous disease, we assayed 30 human AML cell lines by MTS assay 
at 24 and 48-hour time points. Remarkably, 25 of 30 cell lines had EC50 values below 5 
µM, with an average EC50 of 3.2 µM (Figure 2C). The outlier cell line OCI-M2 could be 
an interesting cell line to investigate further in the context of sphingolipid metabolism, 
AC and mechanisms of SACLAC action and/or resistance. SACLAC treatment for 24 
hours slightly reduced normal cell viability. PBMCs (n=6) had an average EC50 of 7.4 
µM while CD34+ (n=4) cells averaged 4.0 µM (Figure S3). These data show that, 
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although there is variability in sensitivity, SACLAC is broadly toxic to AML cells with 
lesser toxicity in normal cells.  
 
SACLAC induces apoptosis and loss of mitochondrial membrane potential  
After confirming that SACLAC treatment reduced cell viability, the mechanism of cell 
death was examined. First, apoptosis induction was evaluated over time in OCI-AML2 
cells treated with SACLAC (5 µM; Figure 3A). Apoptosis was induced as early as 12 
hours (79% apoptosis) with nearly all cells undergoing apoptosis at 24 hours. Loss of 
mitochondrial membrane potential (Figure 3B) occurred in parallel with positive staining 
for the apoptosis marker annexin V (Figure 3A). These patterns were also observed in 
an additional cell line, THP-1 (Figure S4A-B). Additionally, dose-dependent caspase 
activation was observed with SACLAC treatment (Figure 3C). Three human AML cell 
lines exhibited dose-dependent induction of Annexin V staining with 48-hour SACLAC 
treatment, albeit with varying sensitivity (Figure 3D). AML patient samples exhibited 
similar results with more than half the samples reaching 80% apoptosis or greater with 
SACLAC treatment (Figure 3E). These data suggest that apoptosis is the predominant 
mechanism for SACLAC-induced cell death in AML cells. 
 
SACLAC alters the ratio of pro-survival to pro-apoptotic Mcl-1 isoforms 
Next, we investigated mechanisms that mediate apoptosis induction in SACLAC-treated 
OCI-AML2 cells after 24-hour exposure to increasing doses of SACLAC. Since Mcl-1 
has been implicated in AML pathogenesis and specifically in response to sphingolipid 
modulation (22), changes in Mcl-1 with SACLAC treatment were examined. Most 
notably, SACLAC induced a 10-fold upregulation of the Mcl-1S isoform, which 
translated to a 3-fold increase in the ratio of pro-apoptotic Mcl-1S to pro-survival Mcl-1L 
(Figure 4A,C). Since changes in Mcl-1S were observed, splicing factors known to 
regulate Mcl-1 were also examined. SACLAC treatment reduced SF3B1 protein 
expression (Figure 4A-B), suggesting that spliceosome assembly and exon inclusion 
may be disrupted (42). Another splicing factor, SRSF1, was not affected (data not 
shown). Because Mcl-1 can also be cleaved by caspases to generate a smaller protein 
fragment, ABT-737-treated cells were used as a positive control for caspase-mediated 
Mcl-1 cleavage (43). ABT-737 treatment resulted in the expected smaller fragment of 
approximately 22 kDa that was abrogated by co-treatment with caspase inhibitor Z-
VAD-FMK. However, SACLAC treatment led to the appearance of the larger Mcl-1S at 
about 32 kDa, which is the result of alternative mRNA splicing and was not blocked by 
caspase inhibitor treatment (Figure 4D). SF3B1 inhibition with Spliceostatin A (SSA) 
resulted in a dose-dependent increase in Mcl-1S (Figure 4E), which confirm SF3B1’s 
role in Mcl-1 splicing in OCI-AML2 cells. Mcl-1 exon 2 exclusion was confirmed using 
RT-qPCR with primers specific for the Mcl-1S isoform. We observed increased MCL-1S 
transcript in OCI-AML2 cells treated with 5 µM SACLAC (Figure 4F). In order to 
determine if this mechanism is conserved across multiple AML cell lines, we examined 
changes in protein signaling after treating THP-1, HL60-VCR and KG1a cell lines with 
SACLAC for 48 hours. Similar to OCI-AML2 cells, SACLAC reduced SF3B1 levels and 
increased the pro-apoptotic ratio of Mcl-1S/L in all three cell lines (Figure S4C-E). The 
levels of Bim protein isoforms, which represent an alternative downstream readout of 
spliceosome function (44), were also shown to be altered in two cell lines upon 
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SACLAC treatment (Figure S4C). These observations implicate SF3B1 and Mcl-1S in 
SACLAC-mediated intrinsic apoptosis of AML cells.  
 
C16 ceramide treatment and AC knockdown reduce SF3B1 and increase Mcl-1S/L 
ratio 
In order to determine if ceramide is upstream of this mechanistic observation, three 
human AML cell lines were treated with a 100 µg/ml (~150 µM) mixture of ceramides, 
predominantly C18 species and longer. The ceramide mixture induced 60% apoptosis 
with 48-hour treatment (Figure S5A). Treatment with C16 ceramide (20 µM) induced 
similar levels of apoptosis (Figure S5B). Further, treatment with C16 ceramide induced 
similar mechanistic effects as SACLAC, with a reduction in SF3B1 and an increase in 
the ratio of Mcl-1S to Mcl-1L (Figure 5A-C). These data demonstrate that exogenous 
supplementation with ceramides that were shown to increase in response to SACLAC 
treatment (Figure S3) is sufficient to induce apoptosis and alternative Mcl-1 splicing in 
AML. To determine if SACLAC effects on AML cells are dependent on inhibition of AC 
activity, we knocked down AC protein using siRNA. Treatment of KG1a cells with siRNA 
targeting AC reduced AC protein by 76% at 48 hours post-transfection (Figure 5D). At 
this time point, SF3B1 was reduced 37% and the ratio of Mcl-1S to Mcl-1L increased by 
83% (Figure 5E-F). We confirmed in an additional cell line, HL-60/VCR, that shRNA-
mediated AC knockdown led to reduced SF3B1 protein levels, increased Mcl-1S 
expression and Mcl-1S/L ratio as well as altered Bim protein isoform abundance 
(Figure S6). 
 
 
Altering expression of Mcl-1 and SF3B1 attenuates induction of apoptosis in 
SACLAC-treated cells 
Next, we investigated the importance of Mcl-1S in the mechanism of SACLAC-mediated 
cell death. A custom siRNA was designed to target the junction of exons 1 and 3, which 
is present only in the MCL-1S transcript. KG1a cells were electroporated with this 
siRNA and treated with DMSO or SACLAC. Presence of short isoform-specific siRNA 
attenuated the induction of Mcl-1S protein expression upon SACLAC treatment (Figure 
6A). Further, apoptosis induction was reduced by 36% in SACLAC-treated Mcl-1S 
knockdown cells (Figure 6D). Next, we utilized cDNA expression vectors to 
overexpress MCL-1L (Figure 6B) or SF3B1 (Figure 6C) in KG1a cells. Each of these 
conditions led to a partial rescue of apoptosis in SACLAC-treated cells (Figures 6E-F). 
Electroporation of expression vectors led to increased baseline apoptosis in KG1a cells 
(Figure S7). Therefore, the magnitude of SACLAC induced apoptosis after baseline 
subtraction is reduced in Figures 6E-F relative to Figure 6D. In summary, SACLAC 
treatment inhibits AC which leads to increased ceramide and decreased SF3B1. As 
ceramide accumulates, alternative splicing of Mcl-1 results in Mcl-1S accumulation that 
facilitates mitochondrial membrane depolarization. With loss of mitochondrial membrane 
potential (ΔΨm), pro-apoptotic signals are released to activate caspases and induce 
apoptosis (Figure S8). 
 
SACLAC reduces leukemic burden in NSG mouse models of AML 
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Ultimately, we wanted to determine if SACLAC treatment provides therapeutic benefit. 
We first confirmed that our maximum deliverable dose did not exceed a tolerable dose 
for the animals (data not shown). NOD-scid IL2Rgammanull (NSG) immunodeficient mice 
were engrafted with human MV4-11 AML cells and then treated with 5 mg/kg SACLAC 
five times per week by tail-vein injection (Figure 7A). This dose and route of 
administration were chosen based upon studies indicating that IV delivery yields a 
higher maximal serum concentration than IP delivery (Figure S9A). SACLAC exhibited 
a short half-life in the blood (Figure S9A), yet levels of the sphingosine product were 
reduced in the liver for at least 6 hours after treatment (Figure S9B). After 18 injections, 
circulating leukemic cells in the blood were counted using flow cytometry. SACLAC 
treatment resulted in a significant (~75%) decrease in leukemic burden (Figure 7B-C). 
No overt toxicity was observed and SACLAC treated animals exhibited weight gain 
(data not shown). A second, more aggressive model using U937 AML cells (Figure 7D) 
exhibited up to 50% reduction in leukemic cells in the bone marrow of SACLAC-treated 
mice (Figure 7E-F). These data in two preclinical human AML xenograft models 
highlight the potential therapeutic efficacy of SACLAC in AML.  
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DISCUSSION 
 
Here we determined that the AC inhibitor SACLAC kills cells via intrinsic apoptosis 
mediated through a signaling pathway that includes ceramide and Mcl-1S. We showed 
that SACLAC represents a promising compound for further optimization because it is 
broadly cytotoxic across AML cell lines and patient samples. Importantly, SACLAC 
treatment reduces leukemic burden in mice, even at nanomolar serum concentrations.  
 
Our findings build upon previous reports that AC is an emerging therapeutic target that 
regulates the crucial balance between pro-survival S1P and pro-death ceramides 
(14,16,45,46). However, current studies targeting AC in AML are limited. Those that 
exist utilized inhibitors that have overt off-target effects (22) or require large doses for 
cytotoxicity (47). In contrast, SACLAC binds directly to the catalytic site of AC. 
Moreover, therapeutic effects were observed in murine xenograft models despite limited 
ability to deliver high doses of the compound. These in vivo models affirm that SACLAC 
is non-toxic at the administered therapeutic dose. However, in vivo delivery was limited 
by low solubility of the compound. While more work is clearly required to enhance the in 
vivo delivery and clinical potential of SACLAC, our studies present an important 
mechanistic characterization that will inform future optimization of this compound. 
 
Our studies identify a novel association between AC inhibition and alternative splicing in 
AML. Mcl-1 protein is clearly associated with survival of AML cells (24). Mcl-1 and 
sphingolipids have been linked by previous work connecting Mcl-1 with AC (22), S1P 
(48), and ceramide signaling (49). However, these “traditional” relationships focused on 
changes in the full length Mcl-1 protein (Mcl-1L). In contrast, our studies highlight a 
unique mechanism whereby altered splicing leads to a pro-apoptotic Mcl-1 ratio. 
Importantly, this key role for Mcl-1S in SACLAC-mediated cell death is reinforced by a 
partial rescue of viability with knockdown of Mcl-1S as well as overexpression of Mcl-1 
or SF3B1 (Figure 6B,F). These results suggest that alternative splicing of Mcl-1 
cooperates with and compliments other major apoptotic contributors, such as ceramide 
accumulation, S1P depletion and diminished Mcl-1L, to enhance SACLAC-mediated cell 
death.  
 
The relationship between SF3B1 and Mcl-1 has been established (28), and we also 
demonstrated modified protein isoform abundance for an additional target downstream 
of spliceosome function, Bim. The molecular mechanism whereby elevated ceramide 
and/or SACLAC levels lead to SF3B1 reduction is unclear. Ceramides may regulate 
SF3B1 expression through activation of protein phosphatase 1 (PP1) which is known to 
bind the RNA recognition motif of several splicing factors (50). Ongoing studies will 
more fully characterize these mechanisms as well as global changes in transcript splice 
variants, which may also identify factors that drive sensitivity to SACLAC or other 
sphingolipid targeting approaches. 
 
Reduced SF3B1 levels and increased Mcl-1S/L ratios were observed consistently upon 
AC knockdown via both siRNA and shRNA, SACLAC treatment and ceramide 
supplementation (Figures 4, 5 and S6). The AC siRNA knockdown results differed 
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slightly in that loss of Mcl-1L was the major factor in the 2-fold increase of Mcl-1S to 
Mcl-1L compared to primarily increased Mcl-1S upon SACLAC or ceramide treatment 
and changes in both isoforms with AC shRNA. This difference is likely associated with 
variation in temporal dynamics and sphingolipid subcellular distribution associated with 
different types of manipulation. For example, AC activity loss will be more rapid and 
complete with inhibitor treatment relative to siRNA-mediated knockdown. Another likely 
contributor is the abundance of Mcl-1S and L isoforms in KG1a cells relative to other 
AML cell lines (Figure S4C). We previously reported loss of Mcl-1L upon LCL-204 
treatment and AC knockdown in multiple human AML cell lines (22).  LCL204 is known 
to induce lysosomal disruption that likely contributes to the proteasomal degradation of 
Mcl-1 observed in our previous studies, which did not investigate levels of Mcl-1S (22). 
These varying Mcl-1 alterations may relate to the diverse and complex regulatory 
mechanisms that control Mcl-1 transcription, stability and localization (22,51). Indeed, a 
reduction in Mcl-1L levels was also detected after SACLAC treatment in our studies with 
the exogenous overexpression of an Mcl-1L/EGFP fusion protein. Expanding our 
understanding of temporal and spatial relationships when utilizing sphingolipid 
modulators or sphingolipids themselves, as well as the downstream effects on Mcl-1, 
will enhance future therapeutic targeting of sphingolipid metabolism.  
 
The observed changes in SF3B1 and Mcl-1 are particularly interesting since a subset of 
the common somatic mutations in AML involve genes that regulate RNA binding and 
spliceosome assembly (52). Interestingly, myelodysplastic syndrome (MDS), which 
sometimes precedes AML, exhibits spliceosome mutations in about 50% of cases and 
responds noticeably well to spliceosomal inhibition (32). Additional clinical relevance of 
our studies is highlighted by Mcl-1’s known role in resistance to Bcl-2 inhibitor 
venetoclax (ABT-199) (25,53). Venetoclax was recently granted breakthrough status for 
the treatment of newly diagnosed AML in combination with hypomethylating agents or 
low dose cytarabine (54,55). Because of its ability to transition Mcl-1 from pro-survival to 
pro-apoptotic isoforms, SACLAC combination may further enhance the efficacy of 
venetoclax in AML patients and other cancers. SACLAC may also be more beneficial 
than Mcl-1 specific inhibitors in combination therapies due to its pro-apoptotic 
conversion of sphingolipid levels. Ongoing studies in our lab are exploring the relative 
efficacy of SACLAC combinatorial treatments. 
 
The primary limitation for in vivo studies was the poor solubility and limited uptake of 
SACLAC. We were able to improve delivery of SACLAC by changing administration 
route and vehicle (Figure S9A), but only achieved peak serum SACLAC levels of less 
than 1 µM. The control and SACLAC-treated mice were of similar health at termination 
of the study. Nonetheless, we observed significant differences in leukemic burden at the 
cellular level. Identifying improved solvents, alternative formulations or structural 
derivatives of SACLAC may improve therapeutic efficacy. SACLAC-treated mice did not 
lose weight over the course of the study. Future studies will continue to carefully 
evaluate normal bone marrow toxicity as increased SACLAC delivery is achieved. 
  
Our findings are especially important because of AML patient heterogeneity (5). While 
mutation-targeted therapeutics are best suited for specific patient subpopulations, 
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SACLAC appears to exploit a common biochemical dependence across the vast 
majority of AML cell lines and patient samples. While AC upregulation and ceramide 
mediated apoptosis have been established previously (22), we have advanced this field 
by characterizing a novel inhibitor with a unique mechanism of action (Figure 4) and in 
vivo efficacy (Figure 7). Additionally, our screen of 30 AML cell lines represents the 
largest panel of AC inhibitor efficacy studies in AML to date. Further, these studies 
elucidate the mechanism of SACLAC cytotoxicity in AML cells and inform future efforts 
to design combination therapies or combat potential resistance.  
 
Our data support the involvement of AC, ceramide, SF3B1 and Mcl-1 in SACLAC-
mediated apoptosis. However, we cannot completely rule out the possibility of off-target 
or bi-phasic effects of SACLAC. Changes in AC activity, lipid levels and cell viability 
were detected at slightly lower doses than those required to induce robust apoptosis. 
This could mean that cells have a threshold or short-term tolerance for these changes 
upon low dose SACLAC treatment. At higher SACLAC doses, it is plausible that 
additional sphingolipid changes and/or elevated SACLAC levels further increase the 
alterations in SF3B1 and Mcl-1, which cooperate with ceramide accumulation to 
enhance apoptosis induction. Correlation analysis did not identify a significant 
relationship between SACLAC EC50 value and AC enzymatic activity within the 30 cell 
lines. Therefore, SACLAC sensitivity is not simply associated with the levels of the 
enzymatic target. This is likely attributed to the cell line-specific uptake, transport and 
localization of SACLAC (itself a ceramide analog) and sphingolipids as well as the 
varied, cell line-specific biochemical flux within each portion of the complex sphingolipid 
synthesis, catalysis and conversion pathways. Future studies will explore the predictors 
and regulators of SACLAC sensitivity. 
 
Together, our studies demonstrate that ceramide accumulation leading to SF3B1 
reduction and Mcl-1S induction is a primary mechanism of action for novel inhibitor 
SACLAC. Our findings highlight the role of AC and sphingolipids in AML and identify 
SACLAC as a novel compound that informs ongoing lipid-based targeting strategies in 
AML.  
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FIGURE LEGENDS 
 
Figure 1. SACLAC inhibits AC and shifts lipid levels toward a pro-death 
phenotype. A) SACLAC is an ɑ-chloroamide ceramide analog. B) Acid ceramidase 
activity levels were measured by fluorogenic substrate conversion to determine AC 
inhibition after SACLAC (2.5 µM) treatment of HL-60/VCR, THP-1 and OCI-AML2 
human AML cell lines for 24 hours. This experiment was repeated two to three times per 
cell line, and a representative experiment is shown. C) Sphingosine 1-phosphate and D) 
total ceramide levels were measured by mass spectrometry and normalized to total 
protein to determine sphingolipid changes in response to SACLAC (2.5 µM) treatment of 
human AML cell lines for 24 hours. This experiment contained five biological replicates 
and multiple doses with similar response. Statistical analysis was done using two-tailed 
unpaired t-test to compare DMSO and treatment. Lipid data was corrected for multiple 
testing using the Holm-Sidak method. * p < 0.05, ** p < 0.01, *** p < 0.001 relative to 
DMSO control. N.D. indicates values were below the limit of detection.  
 
Figure 2. SACLAC reduces cell viability and colony formation. A) Viability of three 
human AML cell lines was measured by MTS assay after 24-hour treatment with the 
indicated dose of SACLAC. B) Colony formation assay measured clonogenic potential 
in a panel of six primary AML patient samples with increasing doses of SACLAC. This 
experiment contained six distinct patient samples as biological replicates. C) The 
concentration of SACLAC required to achieve a 50% reduction in cell viability (EC50) in 
30 different human AML cell lines was measured by MTS at 24 and 48 hours. Each dot 
represents one MTS assay (n=2-6). Global p-value (ANOVA) is presented on the graph. 
Asterisks denote pairwise comparison from Dunnett’s Test comparing each dose to 
DMSO control. ** p < 0.01, *** p < 0.001. 
 
Figure 3. SACLAC induces apoptosis and loss of mitochondrial membrane 
potential. OCI-AML2 cells were treated with DMSO or SACLAC (5 µM) and evaluated 
for A) apoptosis and B) mitochondrial membrane depolarization at the indicated time. C) 
Caspase 3/7 activation was determined in OCI-AML2 cells treated with increasing 
doses of SACLAC for 24 hours. Dose-dependent apoptosis was measured in D) human 
AML cell lines and E) primary patient samples with 48-hour SACLAC treatment (µM). 
Studies of patient samples were performed once with a panel of seven distinct patient 
samples and the line represents the group mean. Global p-value (ANOVA) is presented 
on the graph. Asterisks denote pairwise comparison from Dunnett’s Test. Dose 
responses are compared to DMSO and time courses are compared to 0-hour time point. 
* p < 0.05, ** p < 0.01, *** p < 0.001. 
 
Figure 4. SACLAC reduces expression of SF3B1 and increases pro-apoptotic Mcl-
1S. A) OCI-AML2 cells were treated with the indicated dose of SACLAC for 24 hours, 
then SF3B1, Mcl-1S and Mcl-1L protein expression was measured by western blot. B) 
SF3B1 and C) Mcl-1S/L ratio were quantified relative to β-actin loading control and 
compared to DMSO vehicle control. D) Alternative splicing of Mcl-1 in OCI-AML2 cells 
treated for 24 hours with SACLAC (5 µM) was clearly distinguished from proteolytic 
cleavage of Mcl-1 induced by ABT-737 (75 nM) as a positive control. Appearance of the 
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Mcl-1 cleavage product, but not Mcl-1S, was blocked by caspase inhibitor Z-VAD-FMK 
(50 µM). E) SF3B1 involvement in Mcl-1 splicing was confirmed using 5 (+), 10 (++) or 
20 nM (+++) spliceostatin A (SSA) to treat OCI-AML2 cells for 6 hours. This experiment 
was repeated twice. F) MCL-1S transcript levels after 6-hour treatment with 5 µM 
SACLAC were measured using RT-qPCR. This experiment was repeated twice. Global 
p-value (ANOVA) is presented on the graph. Asterisks denote pairwise comparison from 
Dunnett’s Test comparing each dose to DMSO control. RT-qPCR analysis utilized two-
tailed unpaired t-test to compare DMSO and treatment. * p < 0.05, ** p < 0.01, *** p < 
0.001. SAC, SACLAC; VAD, Z-VAD-FMK; ABT, ABT-737; SSA, spliceostatin A. 
 
Figure 5. C16 ceramide treatment and AC knockdown reduce SF3B1 and alter 
Mcl-1S to L ratio. A) SF3B1, Mcl-1L and Mcl-1S protein expression was measured by 
western blot after treatment with 20 µM C16 ceramide for 48 hours in OCI-AML2 human 
AML cells. B) SF3B1 and C) Mcl-1S/L ratio were quantified relative to β-actin loading 
control and compared to DMSO vehicle control. D) KG1a cells were electroporated with 
siRNA (50 nM) targeting AC and harvested 48 hours later. Knockdown was confirmed 
and changes in protein levels were evaluated using western blotting. Change in E) 
SF3B1 level and F) Mcl-1S/L ratio were quantified relative to scrambled siRNA as the 
control. Statistical analysis was done using two-tailed unpaired t-test to compare control 
(vehicle or scrambled siRNA) and treatment (C16 or targeting siRNA). * p < 0.05, ** p < 
0.01.  
 
Figure 6. Altering expression of Mcl-1 and SF3B1 attenuates induction of 
apoptosis in SACLAC-treated cells. A) KG1a cells were electroporated with custom 
siRNA (100 nM) targeting the MCL-1S transcript. After 24 hours, cells were treated with 
10 µM SACLAC and analyzed by western blot for Mcl-1S protein expression 48 hours 
later. B) Mcl-1L and C) SF3B1 were overexpressed in KG1a cells by electroporating 
with 15 µg plasmid cDNA and then treated with 7.5 µM SACLAC, respectively, 24 hours 
later. Protein quantification is shown relative to DMSO control following normalization to 
-actin. Mcl-1L is expressed as an Mcl-1/EGFP fusion protein in B; therefore, no 
quantitation is provided in empty vector lanes. The ability of D) Mcl-1S knockdown, E) 
Mcl-1L overexpression and F) SF3B1 overexpression to rescue cells from SACLAC 
mediated cell death was measured by comparing apoptosis induction over baseline 
(apoptosis in DMSO control group) for each condition. Overexpression experiments 
were repeated twice with two doses showing similar results. Statistical analysis utilized 
two-tailed unpaired t-test to compare control (scrambled siRNA or empty vector) and 
treatment (targeting siRNA or cDNA). ** p < 0.01, *** p < 0.001. Lines in blots indicate 
non-adjacent lanes on a single blot at the same exposure. 
 
Figure 7. SACLAC reduces leukemic burden in NSG mouse models of AML. A) 
NOD-scid IL2Rgammanull (NSG) mice (n=3 per group) were injected with 2.5x106 human 
MV4-11 cells labeled with YFP-Luc, and engraftment was confirmed by 
bioluminescence imaging after two weeks. Each animal received five tail-vein injections 
per week of SACLAC (5 mg/kg SACLAC in 45% w/v 2-hydroxypropyl-β-cyclodextrin in 
PBS) or vehicle control. After 18 injections, leukemic burden was measured in blood by 
flow cytometry staining for B) hCD45 and C) YFP markers to identify MV4-11 cells. D) 
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NSG mice (n=5 per group) were injected with 1x104 human U937 cells labeled with 
tdTomato-Luc, and engraftment was confirmed by bioluminescence imaging after one 
week. Each animal received five tail-vein injections per week of SACLAC (5 mg/kg 
SACLAC in 45% w/v 2-hydroxypropyl-β-cyclodextrin in PBS) or vehicle control. After 15 
injections, leukemic burden was measured by flow cytometry staining for E) hCD45 and 
F) tdTomato markers to identify U937 cells in bone marrow. Statistical analysis utilized 
two-tailed unpaired t-test to compare vehicle and SACLAC treatment. * p < 0.05. 
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CELL LINE RRIDs 
 
 
  
CELL LINE RRID 
EOL-1 CVCL_0258 
HEL CVCL_2481 
HL-60 CVCL_0002 
HL-60/ABTR N/A 
HL-60/VCR CVCL_0305 
Kasumi-1 CVCL_0589 
Kasumi-3 CVCL_0612  
Kasumi-6 CVCL_0614  
KG1 CVCL_0374 
KG1/ABTR N/A 
KG1a CVCL_1824 
KG1a/ABTR N/A 
ME-1 CVCL_2110  
ML2 CVCL_1418 
MM-6 CVCL_1426  
MOLM-13 CVCL_2119  
MOLM-14 CVCL_7916  
MV4-11 CVCL_0064 
NB4 CVCL_0005 
NOMO1 CVCL_1609 
OCI-AML2 CVCL_1619 
OCI-AML3 CVCL_1844 
OCI-AML4 CVCL_5224  
OCI-M2 CVCL_2150 
SET2 CVCL_2187 
SKM1 CVCL_0098 
SNKO1 CVCL_2196 
TF-1 CVCL_0559  
THP-1 CVCL_0006  
U937 CVCL_0007 
  
SUPPLEMENTARY FIGURES 
 
 
 
 
Figure S1. SACLAC reduces AC activity at lower doses than LCL204. A fluorogenic 
substrate was used to measure AC activity after treatment with DMSO vehicle, LCL204 
(5 or 10 µM) or SACLAC (1.25 or 2.5 µM) in A) HL-60/VCR, B) THP-1 and C) OCI-AML2 
cell lines. These experiments were repeated twice with equivalent results, and one 
representative experiment is shown. To demonstrate that SACLAC is more potent than 
LCL204, comparisons were done on 4X concentrated LCL204 versus 1X SACLAC (5 vs. 
1.25 and 10 vs. 2.5 µM) using two-tailed unpaired t-test. ** p < 0.01, *** p < 0.001. 
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Figure S2. SACLAC treatment increases production of multiple ceramide species 
in human AML cell lines. Mass spectrometry was used to measure ceramide content 
after treatment with DMSO vehicle or SACLAC (2.5 µM) for 24 hours in A) HL-60/VCR, 
B) THP-1 and C) OCI-AML2 cell lines. The y-axis shown is log10 to accommodate all 
species on an unbroken axis. Each bar represents the mean ± SEM of 5 independent 
biological replicates from a single experiment. Similar response was observed at other 
doses (1.25 and 5 µM) of SACLAC. * p < 0.05, ** p < 0.01, *** p < 0.001. # indicates that 
bar value falls below lower axis limit. Comparison of DMSO versus SACLAC for each 
ceramide species was evaluated using two-tailed unpaired t-test. p-values were corrected 
for multiple testing using the Holm-Sidak method. 
 
  
Figure S2. SACLAC treatment increases production of multiple ceramide species in AML cell lines. 
A B
C
C1
4
C1
6
C1
6:1 C1
8
C1
8:1 C2
0
C2
0:1 C2
2
C2
2:1 C2
4
C2
4:1
C2
4:2 C2
6
C2
6:1
1
10
100
1000
C
er
am
id
e 
(p
m
ol
/m
g 
pr
ot
ei
n)
HL-60/VCR
DMSO
SACLAC
**
***
***
***
**
***
# # # # # # #
C1
4
C1
6
C1
6:1 C1
8
C1
8:1 C2
0
C2
0:1 C2
2
C2
2:1 C2
4
C2
4:1
C2
4:2 C2
6
C2
6:1
1
10
100
1000
C
er
am
id
e 
(p
m
ol
/m
g 
pr
ot
ei
n)
THP-1
DMSO
SACLAC
***
**
*** **
**
***
**
**
# # # #
C1
4
C1
6
C1
6:1 C1
8
C1
8:1 C2
0
C2
0:1 C2
2
C2
2:1 C2
4
C2
4:1
C2
4:2 C2
6
C2
6:1
0.1
1
10
100
1000
C
er
am
id
e 
(p
m
ol
/m
g 
pr
ot
ei
n)
OCI-AML2
DMSO
SACLAC
**
***
***
*** ***
**
***
***
**
***
# ##
  
 
Figure S3. SACLAC is more toxic to AML cells than normal cells. Pooled EC50 
values are depicted for 29 AML cell lines (AML, n=29) and four normal CD34+ samples 
and six normal PBMC samples (Normal, n=10). Comparison of AML cell lines versus 
normal cells was done using two-tailed unpaired t-test. * p < 0.05. 
  
  
 
 
 
Figure S4. SACLAC mechanism of action is consistent in multiple human AML cell 
lines. THP-1 cells were treated with DMSO or SACLAC (10 µM) for 0 to 24 hours and 
evaluated for A) apoptosis and B) mitochondrial membrane depolarization. Data 
presented is from one of two independent experiments with equivalent results. C) THP-
1, HL-60/VCR, and KG1a cells were treated with DMSO (-) or 20 µM SACLAC (+) for 48 
hours and assayed for protein levels via western blotting. A representative blot is shown 
with fold change relative to DMSO and normalized to b-actin (SF3B1) or the specified 
isoform ratios listed below the blots (Mcl-1 and Bim). D) SF3B1 level and E) Mcl-1S/L 
ratio from three independent experiments completed as in panel C were quantified by 
normalizing to β-actin loading and compared to DMSO control. * p < 0.05, ** p < 0.01, *** 
p < 0.001.  For graphs A and B, the global p-value (ANOVA) is presented along with 
asterisks denoting significance of each time point of SACLAC treatment relative to time 0 
using Dunnett’s test. Values in panel C show quantification of Mcl-1L (upper) and Mcl-1S 
(lower) relative to DMSO (set to 1). For graphs D and E, SACLAC treatment was 
compared to DMSO for each cell line and analyzed using two-tailed unpaired t-test.  
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Figure S5. Exogenous ceramides induce apoptosis in human AML cell lines. A) HL-
60/VCR, THP-1 and OCI-AML2 human AML cell lines were treated with long-chain 
ceramide mixture (100 µg/ml) and assayed for apoptosis at 48 hours. B) OCI-AML2 cells 
were treated with DMSO or C16 ceramide (20 µM) for 48 hours and assayed for 
apoptosis. Comparison of vehicle versus ceramide was done using two-tailed unpaired t-
test. *** p < 0.001. Bars represent mean ± SEM of three independent experiments. 
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Figure S4. Exogenous ceramides induce apoptosis in human AML cell lines.
  
 
 
Figure S6. AC knockdown alters splicing of Mcl-1 and Bim in HL-60/VCR cells via 
regulation of SF3B1. HL-60/VCR cells were transduced with lentivirus containing 
shRNA to target AC or GFP control for 96 hours. Western blotting of protein lysates was 
used to confirm AC knockdown efficiency and to determine alterations in the splicing 
protein, SF3B1, and its targets Mcl-1 and Bim. Band intensity in GFP shRNA samples 
was set to 1 for normalization. AC and SF3B1 levels were also normalized to b-actin 
loading control, and the relative values are listed below the blot. For Mcl-1 and Bim, the 
ratio of short to long isoform(s) is shown.  
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Figure S7. Baseline apoptosis varies based on type of electroporated content. Cells 
were electroporated with control (non-targeting siRNA or empty vector) or targeted agent 
(targeting siRNA or targeting cDNA expression vector) and then treated with DMSO 
vehicle control to determine baseline toxicity with each manipulation. 
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Figure S8. Proposed model of SACLAC mechanism of action. SACLAC treatment 
inhibits AC which leads to increased ceramide and decreased SF3B1. As ceramide 
accumulates, alternative splicing of Mcl-1 results in Mcl-1S accumulation that facilitates 
mitochondrial membrane depolarization. With loss of mitochondrial membrane potential 
(DYm), pro-apoptotic signals are released to activate caspases and induce apoptosis. 
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Figure S9. IV administration of SACLAC improves delivery and lipids are shifted in 
mice. SACLAC was administered to Swiss Webster mice intraperitoneally in DMSO (40 
mg/kg) or intravenously in β-HPCD (5 mg/kg). Animals were killed at the indicated time 
points and concentration of A) SACLAC in the blood or B) sphingosine in the liver was 
measured by mass spectrometry. Values represent mean ± SEM from 3 mice per time 
point. Comparison between DMSO and β-HPCD concentration was evaluated using two-
tailed unpaired t-test. Change in sphingosine was evaluated using ANOVA followed by 
Dunnett’s test comparing each time point to 0 hours. * p < 0.05; ** p < 0.01. 
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